HYFT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.540

Open

1.536

VWAP

1.51

Vol

140.89K

Mkt Cap

70.07M

Low

1.475

Amount

212.28K

EV/EBITDA(TTM)

--

Total Shares

46.71M

EV

62.32M

EV/OCF(TTM)

--

P/S(TTM)

3.35

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Show More

Events Timeline

(ET)

2026-06-02

07:30:00

MindWalk Reports Dengue Preclinical Data Validating HYFT Platform Prediction

2026-05-27 (ET)

2026-05-27

08:10:00

MindWalk Holdings Launches Pandemic Response Platform

2026-05-18 (ET)

2026-05-18

08:40:00

MindWalk Holdings Releases Systematic Report Identifying 20 Drug Candidates

2026-03-06 (ET)

2026-03-06

16:10:00

MindWalk Holdings Launches B Cell Llama Platform for Antibody Discovery

2026-01-11 (ET)

2026-01-11

14:50:00

MindWalk Advances Influenza Program Identifying Functional Constraints

2025-10-21 (ET)

2025-10-21

09:12:01

Kamil Isaev Steps Down as MindWalk Director Following Inability to Secure Majority Vote

2025-10-21

09:09:44

MindWalk Names R. Scott Areglado as CFO

2025-10-15 (ET)

2025-10-15

07:04:46

Thomas Lynch named chief business officer at MindWalk

News

PRnewswire

06-16PRnewswire

MindWalk Holdings Bets on Biological Knowledge in Drug Discovery

Newsfilter

06-12Newsfilter

MindWalk CEO to Join Virtual Panel on Drug Discovery

Newsfilter

06-10Newsfilter

MindWalk Launches ReefIQ Biological Data Platform for AI Drug Discovery

Newsfilter

06-02Newsfilter

MindWalk Reports Preclinical Dengue Data Supporting HYFT® Technology

NASDAQ.COM

05-21NASDAQ.COM

HCW Biologics Stock Surges 129% Amid Concerns

Newsfilter

05-18Newsfilter

MindWalk Reports Significant Progress in Drug Development

1 Analyst Rating

Wall Street analysts forecast HYFT stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

JonesResearch

NULL

to

Buy

initiated

$5

AI Analysis

2026-04-15

Reason

JonesResearch

Price Target

$5

AI Analysis

2026-04-15

initiated

NULL

to

Buy

Reason

JonesResearch initiated coverage of MindWalk (HYFT) with a Buy rating and $5 price target. MindWalk offers an end-to-end ecosystem for drug discovery, but "what sets it apart" is its Bio-Native approach, built on a proprietary database of conserved "biological fingerprints, or HYFTs" linking sequence, structure, and function, the analyst tells investor. MindWalk's capabilities span therapeutic areas as well as modalities, attracting partnerships across 19 of the top 20 pharmas in addition to chip maker AMD (AMD), the analyst added.

Valuation Metrics

The current forward P/E ratio for MindWalk Holdings Corp (HYFT.O) is 0.00, compared to its 5-year average forward P/E of -29.94. For a more detailed relative valuation and DCF analysis to assess MindWalk Holdings Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-29.94

Current PE

0.00

Overvalued PE

-18.15

Undervalued PE

-41.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.26

Current EV/EBITDA

-3.85

Overvalued EV/EBITDA

0.25

Undervalued EV/EBITDA

-4.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.46

Current PS

3.49

Overvalued PS

5.92

Undervalued PS

3.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

long call to buy today with highest profit

Intellectia · 13 candidates

Moving Average Relationship: PriceAboveMA20Is Optionable: TrueOption Sentiments: BullishOne Week Rise Prob: >= 60One Week Predict Return: >= 8.0%

Ticker

Name

Market Cap$

Sanmina Corp

7.08B

Agios Pharmaceuticals Inc

1.98B

Resources Connection Inc

124.96M

Ingram Micro Holding Corp

5.40B

Equinox Gold Corp

11.41B

MindWalk Holdings Corp

52.78M

predict most bullish ticker this month

Intellectia · 114 candidates

Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 65One Month Predict Return: >= 10.0%

Ticker

Name

Market Cap$

Spark I Acquisition Corp

98.18M

Apex Treasury Corp

458.22M

Amesite Inc

8.37M

Citizens Financial Services Inc

278.29M

Johnson & Johnson

571.52B

Caribou Biosciences Inc

184.58M

best way to make 10 to 100

Intellectia · 45 candidates

Market Cap: 10.00M - 100.00MWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 0.0%

Ticker

Name

Market Cap$

Aemetis Inc

98.64M

Mind Technology Inc

94.90M

MindWalk Holdings Corp

94.78M

SoundThinking Inc

93.71M

IF Bancorp Inc

91.20M

Sypris Solutions Inc

89.82M

give me 5 more that are bullish

Intellectia · 23 candidates

Price: <= $3.00Weekly Average Turnover: >= 1,000,000Rsi 14: <= 70Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Quarter Eps Qoq Growth: >= 10.0%Quarter Revenue Qoq Growth: >= 10.0%

Ticker

Name

Market Cap$

Companhia Siderurgica Nacional SA

2.36B

Prospect Capital Corp

1.33B

Iovance Biotherapeutics Inc

996.39M

loanDepot Inc

893.07M

Ecarx Holdings Inc.

734.56M

Bit Digital Inc

721.79M

Whales Holding HYFT

Trading Trends

People Also Watch

Frequently Asked Questions

What is MindWalk Holdings Corp (HYFT) stock price today?

The current price of HYFT is 1.5051 USD — it has increased 0.33

What is MindWalk Holdings Corp (HYFT)'s business?

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

What is the price predicton of HYFT Stock?

Wall Street analysts forecast HYFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYFT is5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is MindWalk Holdings Corp (HYFT)'s revenue for the last quarter?

MindWalk Holdings Corp revenue for the last quarter amounts to 4.16M USD, increased 52.42

What is MindWalk Holdings Corp (HYFT)'s earnings per share (EPS) for the last quarter?

MindWalk Holdings Corp. EPS for the last quarter amounts to -0.08 USD, decreased -87.88

How many employees does MindWalk Holdings Corp (HYFT). have?

MindWalk Holdings Corp (HYFT) has 0 emplpoyees as of June 18 2026.

What is MindWalk Holdings Corp (HYFT) market cap?

Today HYFT has the market capitalization of 70.07M USD.